The effects of progesterone hormone applications used for suppression of estrus on mammary glands in queens

Çalışmada kedilerde ilk kızgınlığı baskılamak için kullanılan tek doz medroksiprogesteron asetatın (MPA), serum östradiol 17-β, progesteron, büyüme hormonu seviyelerine ve meme bezinde bu hormonlara ait reseptörler üzerine olan etkileri, kedi meme fibroepitelyal hiperplazi oluşumu ve uygulanan progesteron hormonunun etkinliği araştırıldı. Yirmi adet dişi melez kedi iki eşit gruba ayrıldı. Kedilerin ilk kızgınlıklarının başlangıcı ve bitişi klinik belirtilere ve vaginal smearlara göre tespit edildi. Kızgınlığın ilk günü (Gün -1) kan ve meme dokusu örnekleri kedilerden alındı. Takip eden gün (Gün 0), tedavi (MPA) grubu kedilere 100 mg MPA, kontrol grubu kedilere ise aynı doz fizyolojik tuzlu su intramusküler uygulandı. Kan örnekleri ilk kızgınlık boyunca 3 günde bir ve kızgınlık sonrası 10 günde bir olmak üzere 4 ay boyunca toplandı. Diğer iki meme dokusu örneği 0.günden itibaren 45 gün ara ile toplandı. Serum progesteron seviyeleri çalışmanın 2, 30, 50, 60, 70, 90. günlerinde kontrol grubuna göre tedavi grubunda istatistiki olarak önemli (P

Anahtar Kelimeler:

baskı, kedi, Felis, progestojenler, meme hiperplazisi, kızgınlık, meme bezleri, doku bilimi, ultrasonografi, kızgınlık dönemi

Kedilerde östrusu baskılamak için kullanılan progesteron hormonu uygulamalarının meme bezi üzerine etkileri

The effects of single dose medroxyprogesterone acetate (MPA) applications on serum estradiol 17-β, progesterone, growth hormone levels and their receptors in mammary glands, development of feline mammary fibroepithelial hyperplasia and the efficacy of progesterone hormone for suppression of first estrus in queens were investigated. Crossbred 20 queens were divided into two equal groups. Initiation and the end of the first heats were detected by clinical signs and vaginal smears. At the 1st day of estrus (Day -1) blood and mammary gland tissue samples were taken from the cats. Following day (Day 0), treatment (MPA) group received 100 mg MPA, control group received same dose physiologic saline solution intramuscularly. Blood samples were collected at intervals of 3 day during the first heat and at 10 day intervals thereafter for a period of 4 months. Two other mammary gland samples were collected at intervals of 45 days after Day 0. Serum progesterone levels were significantly (P<0.05) higher on days 2, 30, 50, 60 70, 90 for treated group than control group cats; serum estradiol 17-β levels were significantly (P<0.05) higher on days 20, 30, 40, 50, 70, 100 for control than MPA group of the study. Growth hormone could not be detected throughout the study both in serum and in receptors of the mammary tissue samples. Clinically feline mammary fibroepithelial hyperplasia occurred in a cat and ultrasonography was performed when the lesion first noticed. Tissue samples had significantly higher estrogen receptor labelling for control than MPA group. Highly extensive and dense progesterone receptor positive labelling were observed in all tissue samples. It was concluded that MPA was ef ective to suppress estrus in cats. The incidence of feline mammary fibroepithelial hyperplasia (FMFH) was small. There can be higher incidence of occurring FMFH when used more cat population.

Keywords:

suppression, cats, Felis, progestogens, mammary hyperplasia, oestrus, mammary glands, histology, ultrasonography, oestrous cycle,

PDF

___

1. Romagnoli S, Concannon PW: Clinical use of progestins in bitches and queens: A review. In, Concannon PW, England G, Verstegen J (Eds): Recent advances in small animal reproduction. International Veterinary Information Service, (www.ivis.org) 2003. Document No. A1206.0903, Accessed: 03 March 2007.
2. Concannon PW, Meyers-Wallen VN: Current and proposed methods for contraception termination of pregnancy in dogs and cats. JAVMA, 198 (7): 1214-1225, 1991.
3. Wehrend A, Hospes R, Gruber AD: Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Vet Rec, 17, 346-347, 2001.
4. Hayden DW, Barnes DM, Johnson KH: Morphologic changes in the mammary gland of megestrol acetate-treated and untreated cats: A retrospective study. Vet Pathol, 26, 104-113, 1989.
5. Loretti AP, Ilha MRS, Breitsameter I, Faraco CS: Clinical and pathological study of feline mammary fibroadenomatous change associated with depot medroxyprogesterone acetate therapy. Arq Bras Med Vet Zootec, 56 (2): 270-274, 2004.
6. Loretti AP, Ilha MRS, Ordas J, Martin de las Mulas M: Clinical, pathological and immunohistochemical study of feline mammary fibro- epithelial hyperplasia following a single injection of depot medroxy- progesterone acetate. J Feline Med Surg, 7, 43-52, 2005.
7. Martin de las Mulas J, Millan Y, Bautista MJ, Perez J. Carrosco L: Oestrogen and progesterone receptors in feline fibroadenomatous change: An immunohistochemical study. Res Vet Sci, 68, 15-21, 2000.
8. Mac Dougall LD: Mammary fibroadenomatous hyperplasia in a young cat attributed to treatment with megestrol acetate. Can Vet J, 44 (3): 227- 229, 2003.
9. Feldman EC, Nelson RW: Feline Reproduction. In, Feldman EC, Nelson RW (Eds): Canine and Feline Endocrinology and Reproduction. 3rd ed., pp. 45-60, W.B. Saunders Co, Philadelphia, 2004.
10. Wildt E: Estrous cycle control-induction and prevention in cats. In, Morrow DA (Ed): Current Therapy in Theriogenology 2 (Diagnosis, Treatment and Prevention of Diseases in Small and Large Animals). pp. 808- 812. W.B. Saunders Co, Philadelphia, 1986.
11. Kırşan İ: Dişi kedilerde jinekolojik endokrinoloji. In, Şenünver A, Horoz H, Kılıçarslan R, Ekici H, Konuk C, Kırşan İ (Eds): Veteriner Jinekolojik Endokrinoloji. s. 95-102, Masaüstü Yayımcılık, İstanbul, 1997.
12. Munson L: Contraception in felids. Theriogenology, 66, 126-134, 2006.
13. Misdrop W, Else W, Hellmen E, Lipscomb TP: Histological classification of mammary tumors of the dog and the cat. In, WHO International Histological Classification of Tumors of Domestic Animals. Second Series. Vol. VII., p. 17, Washington DC: Armed Forces Institute of Pathology, 1999.
14. Vitasek R, Dendisova H: Treatment of feline mammary fibroepithelial hyperplasia following a single injection of proligestone. Acta Veterinaria BRNO, 75, 295-297, 2006.
15. Mahler M, Nautrup CP, Schulze C: Fibroepithelial hyperplasie der mamma mit spontaner regression bei einer katze. Kleintierpraxis, 39, 869- 875, 1994.
16. Bastan A, Özenc E, Yagcı İP, Beceriklisoy HB. Mammary hyperplasia in a cat. Ankara Univ Vet Fak Derg, 51, 79-82, 2004.
17. Ordas J, Millan Y, Espinosa de los Monteros A, Reymundo C, Martin de las Mulas J: Immunohistochemical expression of progesterone receptors, growth hormone and insulin growth factor-I in feline fibro- adenomatous change. Res Vet Sci, 76, 227-233, 2004.
18. Güvenç K, Toydemir S, Apaydın S, Kırşan İ: Bir kedide ilk östrustan sonra karşılaşılan fibroepithelyal meme hiperplazisi olgusu. KHVHD, 2 (1): 36-39, 2006.
19. Hayden DW, Johnston SD, Kiang DT, Johnson KH, Barnes DM: Feline mammary hypertrophy/fibroadenoma complex: Clinical and hormonal aspects. AJVR, 42 (10): 1699-1700, 1981.
20. Nak D, Nak Y, Seyrek-İntaş K, Kumru İK: Treatment of feline mammary fibroadenomatous hyperplasia with Aglepristone. Aust Vet Pract, 34 (4):161-162, 2004.
21. Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocrine reviews, 18 (4): 502-519, 1997.
22. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A: Comparison of steroid receptor expression in normal, dysplastic, and neo- plastic canine and feline mammary tissues. Res Vet Sci, 79, 225- 232, 2005.
23. Selman PJ, Mol JA, Ruteman GR, van Garderen E, Rijnberk A: Progestin-induced growth hormone excess in the dog orginates in the mammary gland. Endocrinology, 134 (1): 287-292, 1994.
24. Görlinger S, Kooistra HS, van den Broek A, Okkens AC: Treatment of fibroadenomatous hyperplasia in cats with Aglepristone. JVIM, 16, 710- 713, 2002.
25. Meisl D, Hubler M, Arnold S: Treatment of fibroepithelial hyperplasia (FEH) of the mammary gland in the cat with the progesterone antagonist Aglepristone (Alizine). SAT, 145 (3): 130-136, 2003.